How often is envafolimab administered per week?

Under normal circumstances, the dosing interval for envafolimab is typically 2–4 weeks, depending on the patient's condition, treatment plan, and physician assessment. Specific details are as follows:

For patients with rapidly progressing tumors or those in a critical phase of treatment who are in good physical condition and without severe adverse reactions, a 2-week dosing interval may be adopted after physician evaluation. Shortening the interval helps maintain effective drug concentration more quickly and enhances anti-tumor efficacy, making it particularly suitable for patients requiring intensified therapy with high treatment tolerance. Strict adherence to medical instructions is essential.

If patients experience moderate adverse reactions such as fatigue or rash, or if they are elderly or have underlying conditions that reduce treatment tolerance, a 4-week dosing interval is recommended. Extending the interval reduces drug-induced stress on the body and allows time for recovery, helping prevent worsening of adverse effects. The final decision should be made by the physician based on a comprehensive assessment of the individual patient’s condition.

After administration, closely monitor your physical condition, maintain skin hygiene, and avoid scratching areas affected by rash. Ensure adequate sleep and avoid excessive fatigue. Maintain a balanced diet rich in high-quality protein and vitamins to improve overall treatment tolerance. If any abnormalities such as persistent fever or difficulty breathing occur, record symptoms promptly and seek medical attention to ensure treatment safety.